The Truth About Why We Need This COVID-19 Therapy Proper Now!
On Monday we learnt from Sir Patrick Vallance, the government’s Chief Scientific Adviser that Coronavirus will likely never ever disappear and a vaccine won’t cease it entirely. He also stated that ministers and specialists must quit ‘over-promising’ and be realistic about the prospects of a vaccine and the probably timeline of one, unlikely just before spring next year.
He then echoed his earlier warnings and those of his colleague Professor Chris Whitty that the COVID-19 fight will be a extended 1, and it will be with us for good.
So, from this ought to we assume there is no ‘silver bullet’ for COVID-19 infections?
What if there have been a single treatment that:
could cease the infection in its tracks,
was anti-inflammatory controlling the immune system’s response to the infection and stopping it from overreacting dangerously,
in situations exactly where sufferers developed secondary bacterial infections in the lungs could supercharge antibiotics boosting their efficacy and eve,
was a repurposed drug already confirmed as secure
was straightforward to make, scalable at the level necessary to make a difference in the pandemic and was cost powerful, then wouldn’t that be some thing we need to all be receiving excited about?
Certainly though no such ‘silver bullet’ game altering therapy exists? Following all, the only treatments we hear about for COVID are those which President Trump took, which have been either extremely new, costly and experimental or have a really narrow application to a specific aspect of the disease.
Nicely, you heard it here 1st – such a ‘silver bullet’ therapy does exist now. It is known as Nylexa®, from the tiny UK biotech company NovaBiotics Ltd. It really is active components have been safely employed in medicines that treat unrelated situations for more than 30 years.
NovaBiotics found Nylexa’s prospective rewards in COVID-19 following a decade of study in difficult to treat, drug-resistant infections, like the complicated chest infections and inflammation associated with cystic fibrosis (CF) lung disease. In March they applied for a £1m grant from Innovate UK (representing the government) to get started clinical studies. That grant was sooner or later awarded earlier this month, and the government are now thinking of whether or not to include Nylexa on two separate NHS platform studies.
But why, I hear you ask, if this is so very good have we not heard about it before? Why are the government and the press not shouting about this from the rooftops? Why is this not being demanded by clinicians desperate for helpful therapies for their individuals?
I’m afraid to say, it all boils down to revenue. centerforcovidcontrol.org obtain it tough to get focus as they don’t have the resources readily available to their larger greater funded rivals. The names we study about often when it comes to ground breaking new therapies are invariably large multi-national pharmaceutical organizations with deep pockets and massive budgets to promote their personal unique wares. They make positive their drugs get the required consideration. NovaBiotics is a smaller private enterprise funded by a group of loyal and supportive shareholders so unfortunately do not have the resources to compete for consideration with the huge boys.
Which is why this situation is so frustrating. In mitigating the well being consequences of contracting COVID-19, Nylexa® could increase public confidence of living with the virus for the longer term and potentially permit a higher degree of normality to return to the way in which we reside, benefiting the economy directly in addition to easing COVID-19’s burden on the NHS and healthcare systems globally. But obtaining persons in positions of influence to take notice amongst all the others competing for their attention is quite tricky certainly.
It is reported that there are thousands of prospective COVID-19 therapies in clinical trials across the world. I would challenge any individual to show me one which has the identical potential for good effect as Nylexa®, however this is not presently element of any trial, in spite of its impeccable credentials. So come on UK Government, and ministers, get your finger out and get this drug into trials instantly. The sooner it gets tested, the sooner it can be utilized to aid sort out the mess the pandemic has triggered to all our lives.
About NovaBiotics Ltd
NovaBiotics Ltd is a clinical-stage biotechnology organization focused on the design and style and improvement of initial-in-class therapies for tough-to-treat, medically unmet infectiousdiseases caused by bacteria and fungi and respiratory situations such as cystic fibrosis and COVID-19.
A major innovator in the anti-infectives space, the Company’s robust technology and business enterprise model has been validated via successful development, from concept to late stage clinical development, of its most advanced solution candidates. In addition to the lead Nylexa® programme and the Company’s other late-stage assets (Lynovex® for cystic fibrosis, NP213/Novexatin® for onychomycosis), NovaBiotics has generated a robust pipeline of earlier stage, higher-worth drug candidates including NP339 (Department of Overall health and Social Care funded programme) for life threatening, drug resistant invasive fungal illness and NP432 for multi- drug resistant bacterial infections.